Hydrocortisone acetate 1% / Sodium fusidate 2% ointment
Shortage warning
Current supply issues
High shortage warning
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
Affected areas: UK
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Part of the Fucidin brand family (generic: Hydrocortisone + Sodium fusidate)
MHRA licensed products
View all licensed products for Hydrocortisone + Sodium fusidate on the MHRA register
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 1 · 1958–2025
Showing the 50 most relevant studies, sorted by most relevant.
Yuan Qin, Qian Yi
Clinical Research Communications, 2020
Journal of General - Procedural Dermatology & Venereology Indonesia, 2025
Background: Electrosurgery is a common surgical technique used to treat skin tumors. This procedure produces necrotic skin, which might impair the wound healing process, prompting physicians to prescribe topical antibiotics to prevent infection. This study aims to analyze the efficacy of sodium fusidate ointment compared to petrolatum for wound healing after electrosurgery. Methods: We conducted a double-blind, randomized, controlled study with a within-person design. The inclusion criteria were adult subjects with seborrheic keratosis or acrochordon with a size of 4 mm to 10 mm on the face and neck, with a minimum of 2 lesions. Electrodessication was performed on the subject lesions. The patients were then randomized to receive and sodium fusidate ointment or petrolatum. Follow-up was done for up to 14 days, during which wound healing score, erythema, edema, crusts, re-epithelialization, incidence of infection, and subjective symptoms were assessed. This study is registered in ClinicalTrials.gov (NCT05353374). Results: Twenty-two subjects with 90 wounds were enrolled. The subjects had a mean age of 48.18 ± 11.25 years old and 86.4% of them had seborrheic keratosis. Statistical analysis revealed no significant difference in erythema, edema, crusts, re-epithelialization, infection, subjective symptoms, and total wound healing score appearance on days 3, 7, and 14 following the procedure. Conclusion: Both sodium fusidate ointment and petrolatum showed similar efficacy for wound healing after electrosurgery.
Abstract licence: CC BY-NC
A. Blanco, Giuseppe Zasa
Journal of Clinical Medicine, 2024
S. C. Truelove
BMJ, 1958
S. Jin, Kyeong Soo Kim, D. Kim, et al.
International journal of pharmaceutics, 2016
D. Fulcher, Constance H Katetarts
Medical Journal of Australia, 1991
D. Borroni, C. Mazzotta, C. Rocha-de-lossada, et al.
Biomedicines, 2023
Basem M. Dajani, Naif A. Sliman, Kandil S. Shubair, et al.
The Journal of allergy and clinical immunology, 1981
G. Watkinson
BMJ, 1958
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.